Malin Hultcrantz
Titel
Citeras av
Citeras av
År
Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms
M Björkholm, ÅR Derolf, M Hultcrantz, SY Kristinsson, C Ekstrand, ...
Journal of clinical oncology 29 (17), 2410, 2011
2212011
Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008
M Björkholm, L Ohm, S Eloranta, Å Derolf, M Hultcrantz, J Sjöberg, ...
Journal of Clinical Oncology 29 (18), 2514, 2011
2172011
Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients
C Blimark, E Holmberg, UH Mellqvist, O Landgren, M Björkholm, ...
Haematologica 100 (1), 107-113, 2015
2032015
Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes
SY Kristinsson, M Björkholm, M Hultcrantz, ÅR Derolf, O Landgren, ...
Journal of Clinical Oncology 29 (21), 2897, 2011
1962011
Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study
M Hultcrantz, SY Kristinsson, TML Andersson, O Landgren, S Eloranta, ...
Journal of clinical oncology 30 (24), 2995, 2012
1642012
Risk and cause of death in patients diagnosed with myeloproliferative neoplasms in Sweden between 1973 and 2005: a population-based study
M Hultcrantz, SR Wilkes, SY Kristinsson, TML Andersson, ÅR Derolf, ...
Journal of Clinical Oncology 33 (20), 2288-2295, 2015
662015
Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population-based cohort study
M Hultcrantz, M Björkholm, PW Dickman, O Landgren, ÅR Derolf, ...
Annals of internal medicine 168 (5), 317-325, 2018
622018
Patients with polycythemia vera have worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasms
J Abelsson, B Andréasson, J Samuelsson, M Hultcrantz, E Ejerblad, ...
Leukemia & lymphoma 54 (10), 2226-2230, 2013
582013
Clinical responses and pharmacokinetics of MCARH171, a human-derived Bcma targeted CAR T cell therapy in relapsed/refractory multiple myeloma: final results of a phase I …
S Mailankody, A Ghosh, M Staehr, TJ Purdon, M Roshal, E Halton, ...
Blood 132 (Supplement 1), 959-959, 2018
432018
Leukemic transformation in myeloproliferative neoplasms: therapy-related or unrelated?
M Björkholm, M Hultcrantz, ÅR Derolf
Best Practice & Research Clinical Haematology 27 (2), 141-153, 2014
392014
Second malignancies in patients with myeloproliferative neoplasms: a population-based cohort study of 9379 patients
AR Landtblom, H Bower, TML Andersson, PW Dickman, J Samuelsson, ...
Leukemia 32 (10), 2203-2210, 2018
312018
Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10–49 years old: a population-based study from the National Health …
O Landgren, BI Graubard, S Kumar, RA Kyle, JA Katzmann, K Murata, ...
Blood cancer journal 7 (10), e618-e618, 2017
292017
Dramatically improved survival in multiple myeloma patients in the recent decade: Results from a Swedish population-based study
S Thorsteinsdottir, PW Dickman, O Landgren, C Blimark, M Hultcrantz, ...
Haematologica 103 (9), e412, 2018
282018
Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy provides unprecedented MRD negativity rates in newly diagnosed multiple myeloma: a …
O Landgren, M Hultcrantz, AM Lesokhin, S Mailankody, H Hassoun, ...
Blood, The Journal of the American Society of Hematology 134 (Supplement_1 …, 2019
212019
Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma
S Mailankody, D Kazandjian, N Korde, M Roschewski, E Manasanch, ...
Blood advances 1 (22), 1911-1918, 2017
212017
Elevated risk of venous but not arterial thrombosis in W aldenström macroglobulinemia/lymphoplasmacytic lymphoma
M Hultcrantz, RM Pfeiffer, M Björkholm, LR Goldin, I Turesson, ...
Journal of Thrombosis and Haemostasis 12 (11), 1816-1821, 2014
202014
MRD testing in multiple myeloma: the main future driver for modern tailored treatment
O Landgren, SX Lu, M Hultcrantz
Seminars in Hematology 55 (1), 44-50, 2018
192018
Association of immune marker changes with progression of monoclonal gammopathy of undetermined significance to multiple myeloma
O Landgren, JN Hofmann, CM McShane, L Santo, M Hultcrantz, N Korde, ...
JAMA oncology 5 (9), 1293-1301, 2019
182019
Multiple myeloma and its precursor disease among firefighters exposed to the World Trade Center disaster
O Landgren, R Zeig-Owens, O Giricz, D Goldfarb, K Murata, K Thoren, ...
JAMA oncology 4 (6), 821-827, 2018
172018
Elevated risk of venous but not arterial thrombosis in W aldenström macroglobulinemia/lymphoplasmacytic lymphoma
M Hultcrantz, RM Pfeiffer, M Björkholm, LR Goldin, I Turesson, ...
Journal of Thrombosis and Haemostasis 12 (11), 1816-1821, 2014
172014
Systemet kan inte utföra åtgärden just nu. Försök igen senare.
Artiklar 1–20